Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hisamitsu seeks barriers for Salonpas generics

This article was originally published in The Tan Sheet

Executive Summary

Hisamitsu Pharmaceutical Co. petitions FDA to require generic competition for its Salonpas Pain Relief Patch to submit specific clinical data as part of abbreviated new drug applications. The agency should reject any ANDA without a placebo-controlled clinical investigation, a standard battery of skin safety studies and a pharmacokinetic study centered on the generic patch formulation, the Japanese firm says in its Dec. 31 citizen 1petition. Further, the generic product should have the same surface area and active ingredient amounts as Salonpas, Hisamitsu says. FDA approved Salonpas' NDA in February 2008, and the company says it is unaware of any other successful NDAs for OTC topical external analgesics (2"The Tan Sheet" Sept. 1, 2008, In Brief). Reckitt Benckiser used a similar strategy in a bid to raise the bar for generic versions of Mucinex, but FDA denied its petition (see story p. 5)

Related Content

Salonpas patch packaging





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts